Table 4

Sensitivity analyses restricted to 2006–2012, on first tumour necrosis factor inhibitor (TNFi) (‘on drug’) and continuous time on TNFi treatment (“on class’), respectively

Analysis	Outcome	Cohort comparison	n events	Person-years	HR*
2006–2012 and stricter definition of biologics-naive RA†	CIN 1	TNFi	40	41 938	1.02 (0.67 to 1.54)
		New TNFi users‡	21	16 725	1.12 (0.67 to 1.87)
		Biologics-naive RA	59	88 696	Ref
		General population	637	1 394 519	0.59 (0.45 to 0.78)
	CIN 2+	TNFi	58	42 429	1.10 (0.72 to 1.68)
		New TNFi users‡	30	16 916	1.09 (0.72 to 1.66)
		Biologics-naive RA	89	89 385	Ref
		General population	1003	1 403 802	0.59 (0.47 to 0.73)
	Invasive cervical cancer	TNFi	10	45 557	1.36 (0.59 to 3.13)
		New TNFi users‡	1	18 110	§
		Biologics-naive RA	17	94 590	Ref
		General population	207	1 474 695	0.73 (0.44 to 1.21)
On drug	CIN 1	TNFi	30	29 094	1.23 (0.81 to 1.88)
	CIN 1	Biologics-naive RA	99	173 369	Ref
	CIN 2+	TNFi	50	29 407	1.60 (1.15 to 2.22)
	CIN 2+	Biologics-naive RA	137	174 514	Ref
	Invasive cervical cancer	TNFi	5	31 499	1.46 (0.54 to 3.94)
	Invasive cervical cancer	Biologics-naive RA	25	184 391	Ref
On class	CIN 1	TNFi	37	36 699	1.21 (0.82 to 1.78)
	CIN 1	Biologics-naive RA	99	173 369	Ref
	CIN 2+	TNFi	59	37 100	1.50 (1.09 to 2.05)
	CIN 2+	Biologics-naive RA	137	174 514	Ref
	Invasive cervical cancer	TNFi	8	39 845	1.81 (0.78 to 4.18)
		Biologics-naive RA	25	184 391	Ref

HRs (HRs model a–c) and 95% CIs comparing each outcome between cohorts.
*Stratified on decade of birth and adjusted for educational level, number of cervical screens past five years, comorbidities, marital status and total days spent in hospital during last five years, also implicitly adjusted for age since age was used as the model's timescale.
†The biologics-naive RA cohort was restricted to patients who initiated or were on treatment with at least two of any of the commonly used non-biological DMARDs (methotrexate, sulfasalazine, antimalarials or leflunomide).
‡TNFi cohort restricted to patients who started their first TNFi treatment 2006 or later.
§Not computed due to low number of events.
CIN, cervical intraepithelial neoplasia; DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis.